English
Syloid® FP Pharmaceutical Silica: Full-Link Empowerment for the New Future of Pharmaceutical Manufacturing
Created on 02.27
Syloid® FP Pharmaceutical Silica: Full-Link Empowerment for the New Future of Pharmaceutical Manufacturing
The Syloid® FP series of pharmaceutical silica is a multi-functional pharmaceutical excipient launched by Grace. It has completely broken through the positioning of traditional excipients as merely inert fillers/processing aids. With its exclusive controllable mesoporous structure, ultra-high purity, and globally unified pharmaceutical-grade production standards, it can simultaneously achieve multiple functions such as glidant, anti-adhesion, moisture-proof, adsorption, and dissolution promotion, significantly improving preparation production efficiency, drug dissolution rate, storage stability, and therapeutic effectiveness. It complies with the global mainstream pharmacopoeia standards of USP-NF, EP, and JPE, and holds the industry's first IPEA excipient GMP certification. It can help pharmaceutical companies shorten the new drug launch cycle, reduce supply chain and R&D risks, and is suitable for the development of various preparations such as innovative drugs and biosimilars, serving as a core strategic excipient for the development of drug delivery systems in the pharmaceutical industry.
I. Core Product Positioning and Strategic Value
Traditional pharmaceutical excipients are often regarded as inert components/processing aids, while the Syloid® FP series of pharmaceutical silica launched by Grace is a strategic pharmaceutical excipient with multiple functions, which can create core value for pharmaceutical enterprises from the entire R&D, production, and commercialization links:
1. Enhance Profitability: The correct selection of this excipient can significantly affect production efficiency, drug dissolution rate, therapeutic effectiveness, and formulation stability, adapting to the development of biosimilars, mixed preparations, etc. Early intervention in R&D can shorten the new drug launch cycle and improve the commercialization success rate of new chemical entities (NCEs) and new biological entities (NBEs).
2. Reduce Full-Link Risks: It can avoid risks such as supply chain disruption, formulation stability failure, and new drug R&D failure caused by low-cost excipients. Choosing compliant excipients that have been approved and produced by leading manufacturers can reduce operational errors, improve supply chain transparency, and meet the R&D requirements of Quality by Design (QbD).
II. Compliance and Global Quality Assurance
1. Global Mainstream Pharmacopoeia Compliance
Syloid® FP silica fully complies with the three major global mainstream pharmacopoeia standards and can support drug registration in multiple regions around the world. The specific compliance information is as follows:
Pharmacopoeia Standard | Corresponding Compliance Items |
United States Pharmacopeia - National Formulary (USP-NF) | Special test requirements for silica |
European Pharmacopoeia (EP) | Special test requirements for colloidal hydrated silica |
Japanese Pharmacopoeia Excipient Standards (JPE) | Special test requirements for hydrated silica |
2. Authoritative Certifications and Quality Control System
• Grace is the world's first enterprise to obtain IPEA excipient GMP certification. Its production bases have also passed ISO 9001 certification, complying with REACH regulations, and achieving continuous quality improvement through the LEAN Six Sigma® system.
• Full-link traceable supply chain: Grace conducts original factory production, fully controls the supply chain supervision, and ensures supply stability and batch consistency.
• Global production layout: The products are produced in three major bases: Worms (Germany), Baltimore (USA), and Sorocaba (Brazil), ensuring stable global supply.
III. Core Technology and Product Differentiation Characteristics
1. Industry-Leading Exclusive Manufacturing Technology
Grace is the world's first enterprise to commercialize silica in 1921. Its Syloid® FP series has exclusive manufacturing processes, building core technical barriers:
• Customized mesoporous structure design: The production process can prepare micro-powders with precisely controllable pore structures. Different functional customizations can be achieved by adjusting the internal porosity, and the developed mesoporous network is the basis for the core performance of the product.
• Exclusive purification process: The unique metal ion removal step can eliminate the risk of drug incompatibility caused by metal ions, and greatly improve product purity and batch stability.
2. Core Product Models and Exclusive Functions
The Syloid® FP series has developed differentiated models for different formulation pain points. The characteristics and application scenarios of the core models are as follows:
Product Model | Core Characteristics | Core Application Scenarios |
Syloid® AL-1FP | Excellent moisture control capability | Protection of moisture-sensitive APIs, moisture-proof of hygroscopic materials, effervescent tablet formulations, moisture adsorption of capsules, and extension of product shelf life |
Syloid® 244FP | Ultra-high porosity and adsorption capacity, capable of adsorbing 3 times its own weight in liquid | Powderization of liquid raw materials, improvement of dissolution of poorly soluble drugs, promotion of ODT disintegration, anti-adhesion of enteric coating, and adsorption of oil phase/lipid systems |
Syloid® 72FP | Excellent viscosity adjustment and suspension stability capabilities | Gelation of liquid preparations, prevention of stratification in suspension systems, stabilization of aroma components, and development of cream/paste preparations |
3. Core Performance Comparative Advantages
Compared with similar products such as fumed silica, the Syloid® FP series has higher porosity, larger internal specific surface area, and stronger adsorption capacity. It can achieve multiple functions simultaneously, reduce the types of excipients in the formulation, simplify the production process, and reduce comprehensive costs.
IV. Core Gains in Formulation Production and Performance
1. Core Gains at the Production and Manufacturing End
• Powder process optimization: It can improve powder fluidity under different relative humidity conditions, adapt to the direct compression process, improve glidability and mixing uniformity, reduce the pre-use sieving process, and avoid valve blockage during production.
• Tablet quality improvement: Tablet hardness can be improved under lower compression force, reducing the risk of friability, capping, and layering, and reducing the batch unqualified rate.
• Production compliance and loss control: It has antistatic properties, reducing API material loss; higher bulk density reduces dust generation, making it easier to meet GMP compliance requirements, and saving space in warehousing.
2. Core Gains at the Formulation Performance End
• Stability improvement: It can protect moisture-sensitive APIs, block environmental moisture, inhibit the water absorption of hygroscopic materials, adsorb the liquid precipitated during tablet compression and the condensed moisture of capsule shells, and ensure the long-term storage stability of products.
• Bioavailability improvement: It can significantly improve the wettability and dissolution curve of poorly soluble drugs, addressing the core industry pain point — currently, 40% of marketed drugs and 70% of in-development APIs have poor solubility. This product can improve the drug dissolution rate through its porous structure, thereby enhancing bioavailability.
• Multi-formulation adaptability: It can be used as a carrier for liquid raw materials to achieve powderization, a stabilizer for oil suspension systems, an anti-adhesive for enteric/sustained/controlled release coatings, a taste-masking excipient, a transdermal preparation excipient, etc. It is suitable for the development of various cutting-edge formulations such as liquid-solid preparations, high drug-loading preparations, and SEDDS lipid-based drug delivery systems.
V. R&D Innovation and Full-Industry Chain Solutions
1. Continuous R&D and Strategic Cooperation
• Independent R&D directions: Including customized pore-adjusted silica, permeation-enhancing excipients, functional co-processed excipients, mixed preparations, sustained/controlled release/enteric coating technologies, etc.
• Strategic cooperation: In-depth cooperation with Formac Pharmaceuticals, combining the latter's high-throughput screening platform with Grace's silica R&D and production capabilities to develop the optimal silica-drug combination and overcome the industry problem of bioavailability of poorly soluble drugs.
2. Grace's Full-Industry Chain Pharmaceutical Solutions
Grace can provide full-process solutions from drug discovery to market delivery, covering the entire pharmaceutical cycle:
1. Discovery Phase: Reveleris® Flash Chromatography Systems and Grace® Silica Gels help medicinal chemists complete NCE development and purification faster.
2. Synthesis Phase: Synthetech custom peptide building blocks and specialty amino acids support clinical development and API production.
3. Purification Phase: Davisil®, Vydac® Purification Media, Spring® Chromatography Columns, etc., cover purification needs from pilot scale to industrial scale.
4. Delivery Phase: Syloid® FP series pharmaceutical silica empowers formulation development and innovation of drug delivery systems.
3. Global Service Layout
Grace has established technical and service outlets in many parts of the world, including Chicago/Columbia (USA), Worms (Germany), Shanghai (China), Hyderabad (India), Lokeren (Belgium), Rowville (Australia), etc., providing localized technical and commercial support for global pharmaceutical enterprises.
VI. Compliance Statement
All data in this document are derived from Grace's internal tests and practical application experience. Due to differences in user operating conditions, Grace does not guarantee the corresponding results; product specifications and prices are subject to change without prior notice. All related trademarks belong to W. R. Grace & Co.-Conn. and its subsidiaries.
---
Key Questions and Corresponding Answers
Question 1 (Strategic Positioning Dimension): Why can Syloid® FP silica break through the positioning of traditional pharmaceutical excipients and become a strategic tool for pharmaceutical enterprises in formulation development?
Answer:
1. Essential Breakthrough in Functional Dimension: Most traditional excipients only undertake a single basic function such as filling and glidant, while Syloid® FP silica can simultaneously achieve multiple functions such as glidant, anti-adhesion, moisture-proof, adsorption, dissolution promotion, and viscosity adjustment through its controllable porous structure. It can reduce the types of excipients in the formulation, simplify the production process, and fundamentally optimize the formulation design logic.
2. Value Empowerment Throughout the Life Cycle: This excipient can shorten the new drug launch cycle and improve the commercialization success rate of NCEs/NBEs at the R&D end; improve manufacturing efficiency and reduce material loss and quality risks at the production end; extend product shelf life and improve drug therapeutic effect at the market end. It covers value creation throughout the entire life cycle of drugs, rather than just serving as an auxiliary material in the production link.
3. Precise Solution to Core Industry Pain Points: Aiming at the long-standing pain point of bioavailability of poorly soluble drugs in the pharmaceutical industry (40% of marketed drugs and 70% of in-development APIs have poor solubility), this product can significantly improve the drug dissolution rate and bioavailability. At the same time, it is suitable for the development of cutting-edge formulations such as biosimilars, mixed preparations, and liquid-solid preparations, becoming the core carrier for the innovation of drug delivery systems.
4. Compliance Adaptation for Global R&D and Registration: The product complies with the three major global mainstream pharmacopoeia standards and holds the industry's first IPEA excipient GMP certification, which can meet the requirements of the QbD R&D system, helping pharmaceutical companies reduce global registration and supply chain risks and become the core strategic choice for global formulation development.
Question 2 (Risk Control Dimension): In what aspects can pharmaceutical enterprises reduce risks in the process of formulation development and commercialization by choosing Syloid® FP silica?
Answer:
1. Reduction of Supply Chain and Supply Safety Risks: As the original manufacturer, Grace realizes full-link traceable supply chain and full-process supervision, with three global production bases in Germany, the United States, and Brazil. It can avoid common risks of low-cost excipients such as supply disruption, unstable batch quality, and difficulty in traceability, ensuring the continuity of supply for commercial pharmaceutical production.
2. Reduction of Compliance and Global Registration Risks: The product fully complies with the three major global mainstream pharmacopoeia standards of USP-NF, EP, and JPE. Its production bases have passed authoritative certifications such as ISO 9001 and IPEA excipient GMP. It is a mature pharmaceutical excipient approved globally, which can greatly reduce the compliance risks of pharmaceutical companies in global drug registration and shorten the regulatory review cycle.
3. Reduction of Formulation R&D and Performance Failure Risks: The product features an exclusive purification process that removes metal ions prone to causing drug interactions, thereby enhancing purity and batch consistency, and mitigating the risk of incompatibility between excipients and APIs. Concurrently, its stable physical and chemical properties ensure the long-term storage stability of formulations, averting risks such as formulation failure, R&D failure, and post-market recalls stemming from excipient issues.
4. Reduction of Production and Quality Compliance Risks: The product can optimize powder fluidity, reduce dust and API loss, and reduce production quality problems such as tablet friability/capping/layering, thereby reducing the risks of production operational errors and batch unqualified rates. The low-dust characteristic makes it easier to meet GMP production compliance requirements, reducing the quality and compliance cost risks at the production end.
Question 3 (Technical Application Dimension): Which core application scenarios in the pharmaceutical industry are suitable for different models of Syloid® FP series silica, and what specific formulation pain points do they solve?
Answer:
The Syloid® FP series has developed differentiated models for different formulation pain points. The adaptation scenarios and pain point solutions of the core models are as follows:
Syloid® AL-1FP: It is mainly positioned as a special model for moisture control, focusing on solving moisture-related pain points in formulations. It can protect moisture-sensitive APIs from hydrolysis and failure, inhibit the water absorption of hygroscopic materials, adsorb the condensed moisture of capsule shells and the liquid precipitated during tablet compression, and reduce the moisture intake of effervescent tablet formulations. It fundamentally solves the problems of formulation degradation, shelf life shortening, and insufficient stability caused by moisture, ensuring the long-term storage stability of formulations.
2. Syloid® 244FP: It is mainly positioned as a model with ultra-high adsorption capacity, capable of adsorbing 3 times its own weight in liquid, focusing on solving two core pain points: solidification of liquid raw materials and dissolution of poorly soluble drugs. It can convert liquid APIs, oils, flavors, and other components into directly compressible powders, achieving high drug loading and solving the industry problem that liquid raw materials are difficult to prepare into solid preparations. At the same time, it can significantly improve the wettability of tablets, promote the rapid disintegration of ODT, improve the dissolution rate and bioavailability of poorly soluble drugs, and also serve as an anti-adhesive for enteric/sustained/controlled release coatings, solving problems such as tablet sticking and uneven coating during the coating process.
3. Syloid® 72FP: It is mainly positioned as a model for viscosity adjustment and suspension stability, focusing on solving pain points such as stratification, viscosity control, and insufficient stability of liquid preparations and semi-solid preparations. It can convert liquids into clear gels, creams, or pastes, adapting to the development of semi-solid preparations and transdermal preparations. At the same time, it can prevent the stratification of materials in suspension systems, stabilize oil suspension systems, and achieve stable storage of aroma components, adapting to the development needs of various formulations such as liquid preparations, chewable preparations, and external preparations.
The news and information released by Zhonglian Chemical is provided solely for informational purposes and is intended only for reference and communication among industry professionals. It does not guarantee the accuracy and completeness of such information. You should not use this information to replace your own independent judgment; therefore, you shall bear the risks arising from any use of the information, and Zhonglian Chemical shall not be held liable. In case of any infringement, please contact us for removal.
Contact
Leave your information and we will contact you.
Phone
WeChat
WhatsApp